matt mindset releas full result pre-
announc revenu deliv strong revenu
grow y/i ep vs con call note
two import data point increment pre-announc firstli
comment us tax reform lower tax rate vs
tax reform also enabl repatri cash give opportun invest
result increas opex spend area like
grow commerci oper ou comput assist surgeri like call
histor achiev high roi intern invest view
present particularli import time invest competitor
look get market hit cylind think
upsid guidanc rais pt account ep upsid due
slight bump revenu assumpt tax base ep
prior target base prior ep concern
valuat potenti competit larger competitor mdt/jnj
see issu least
expect procedur growth bracket consensu
view modestli conserv given recent trend upcom
catalyst guidanc includ minim contribut sp phase launch
year remind applic file last month reimburs
addit indic japan recent recommend addit
quota da vinci china yet updat note
quota could still potenti impact approv stapler
submiss see reason busi momentum slow
longer term highlight compel pipelin includ flexibl robot
revenu contribut on-going test diagnosi lung cancer
futur indic da vinci imag
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight isrg core market stabl
think continu beat number drive
growth new area bullish potenti
market growth gener thorac surgeri
see ou expans especi japan china
new sp product ai imag
advanc flexibil cathet platform key
ou market uptak robot surgeri
contribut new instrument sp
flexibl robot pipelin advanc new quota
china indic japan
pushback cost robot surgeri
competit other recal
guidanc seem conserv us given catalyst
expect procedur growth bracket consensu
view modestli conserv given recent trend catalyst
think includ limit contribut sp although announc file
applic da vinci singl port sp system urolog plan phase
launch year catalyst could includ addit quota china
time uncertain reimburs indic japan
recommend mhlw level reimburs determin agenc
end quarter comment expect weakest quarter
year given season headwind fewer surgeri day due
place total system includ us ou total system
revenu grew y/i vs y/i growth y/i
growth y/i growth placement us ou increas y/i
significantli quarter system place oper leas vs
revenu gener oper leas
procedur us gener urologylsdmsdurolog growth moder toward incidenceu gynecology-modestli modestlyu gener surgerymoderatemoderatelaw larg numbersouschinaquota latequota earlyjapanno new indicationsnew indic apriloper invest sever strateg interest incomeadj tax reform benefitshar mm impli quarter season weakest friday headwindshar lower reflect higher cost associ new productsno guidanc barclay intuit surgic
quarter vs revenu oper leas
recogn ratabl cours leas
mhlw ministri labor welfar japan recommend
procedur reimburs howev rate reimburs yet
set end quarter reimburs rate determin offer
clariti opportun expect system growth modest
japan year system alreadi instal countri
isrg gross margin vs annual guidanc rang con
rel gm increas manufactur cost fell off-set higher mix
system sale due season go forward gm variabl depend mix
new product mix system instrument accessori revenu
system manufactur effici
sp submit decemb
comment progress da vinci sp program remind sp
robot singl port system offer vision high level dexter confin
space submit decemb previous guid
submiss toward end continu plan begin urolog head
neck colorect surgeri market initi sp devic test
human trial us hong kong urolog head neck colorect
expect phase launch sp year
flexibl robot program comment make progress
target need diagnosi lung cancer among commonli
diagnos cancer global earli detect make major clinic
differ system test australia last year preliminari data disclos
chest annual confer revenu program expect
result detail much pick
revenu grew y/i vs con ep vs con
segment instrument accessori revenu report
con system revenu con
servic revenu also con
procedur grew vs con also ship unit
includ oper leas arrang compar con
revenu per procedur last year last quarter
gross margin increas sequenti increas y/i
effect tax rate quarter vs
us procedur grew ou growth total procedur growth
vs consensu expect momentum gener surgeri
us urolog procedur europ japan multispecialti procedur grow
korea china
us gener surgeri exceed gynecolog isrg largest specialti
run-rat basi growth driven gener surgeri includ hernia repair
ventral inguin earli stage uptak bariatr procedur us gynecolog
continu see trend toward use physician specialist
complex benign cancer surgeri physician tend user overal
growth us prostatectomi exceed isrg expect quarter full year
note us growth also like higher surgeri defer result
hurrican move
outsid us procedur growth driven increas use da vinci
prostatectomi increas util kidney procedur gynecolog
also earlier stage growth gener surgeri importantli surgeri volum
may lower due level util system china expect
make increment system sale china year
revenu mm
ep
intuit surgic mm except ep actualconsensu barclay intuit surgic
intuit surgic growthbarclay non-gaap ex tax dilut mm except ep actualbarclay consensu barclay intuit surgic
mm except updat growth growth gross growth growth non-gaap ex ebitda non-gaap ex ebit pre-tax tax net net average share increas ex increas inc increas barclay intuit surgic
matthew taylor cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur issuer
 employe non-execut director barclay bank plc and/or affili director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past month
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic issuer
within next month
fa barclay bank plc and/or affili benefici own class equiti secur issuer calcul accord
us regul
fb barclay bank plc and/or affili benefici own long posit class equiti secur issuer
calcul accord eu regul
fc barclay bank plc and/or affili benefici own short posit class equiti secur issuer
calcul accord eu regul
gd one analyst fundament credit coverag team member household financi interest debt
equiti secur issuer
ge one analyst fundament equiti coverag team member household financi interest debt
